Laura Mulloy

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

RANDOMIZED TRIAL OF TACROLIMUS (PROGRAF) IN COMBINATION WITH AZATHIOPRINE OR MYCHOPHENOLATE MOFETIL VERSUS CYCLOSPORINE (NEORAL) WITH MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION1, 2

Christopher P. Johnson, Nasimul Ahsan, Thomas A. Gonwa et al. · Transplantation · 2000 · 296 citations

Pharmacy, Nephrology, Pharmacotherapy +17

EFFECTS OF TACROLIMUS ON HYPERLIPIDEMIA AFTER SUCCESSFUL RENAL TRANSPLANTATION

Thomas R. McCune, Leroy R. Thacker, Thomas G. Peters et al. · Transplantation · 1998 · 150 citations

Medicine, Nephrology, Pharmacology +15

Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years

Thomas A. Gonwa, Christopher P. Johnson, Nasimul Ahsan et al. · Transplantation · 2003 · 143 citations

Medicine, Nephrology, Pharmacotherapy +15

RANDOMIZED TRIAL OF TACROLIMUS PLUS MYCOPHENOLATE MOFETIL OR AZATHIOPRINE VERSUS CYCLOSPORINE ORAL SOLUTION (MODIFIED) PLUS MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION: RESULTS AT 2 YEARS1

Nasimul Ahsan, Christopher P. Johnson, Thomas A. Gonwa et al. · Transplantation · 2001 · 140 citations

Medicine, Nephrology, Pharmacotherapy +17